General Information of the Disease (ID: DIS00069)
Name
Parkinson disease
ICD
ICD-11: 8A00
Full List of Target(s) of This Ferroptosis-centered Disease
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 3 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Cyperquat Investigative
Responsed Regulator Thioredoxin (TXN) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model PC12 cells Adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
Male C57BL/6 mice wild-type (WT), 8 weeks of age, were from Chongqing Medical University, China. Mice were divided into four groups (n = 10-13 per group), control group, MPTP group, h-Trx-1 Tg group, and h-Trx-1 Tg + MPTP group. Control and h-Trx-1 Tg groups were administered saline only. For the Trx-1 knockdown experiment, mice were divided into six groups (n = 10-13 per group), control + saline group, control + MPTP group, AAV9-vehicle + saline group, AAV9-vehicle + MPTP group, AAV9-shRNA-mTrx-1 + saline group, and AAV9-shRNA-mTrx-1 + MPTP.

    Click to Show/Hide
Response regulation 1-methyl-4-phenylpyridinium (Cyperquat) decreased cell viability, GPX4, and Trx-1 (TXN). The decreased GPX4 and GSH, and increased ROS were inhibited by Fer-1 and Trx-1 overexpression. Trx-1 reversed the decreases of GPX4 and tyrosine hydroxylase (TH) induced by MPTP in the substantia nigra pars compacta (SNpc). Trx-1 inhibits ferroptosis in parkinson's disease through regulating GPX4 and GSH.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [11]
Target for Ferroptosis Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Oxidopamine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
The AB strain of wild-type zebrafish (Danio rerio) was applied in this study. Zebrafish larvae at 4 dpf (days post-fertilization) were co-incubated with 250 uM 6-OHDA or 1.5 ug/mL nomifensine (Nomi, a dopamine transporter inhibitor) in 6-well plates at a density of 30 zebrafish embryos per group for 2 days and the medium was refreshed every day. The swimming total distance of each fish was recorded for 10 min and was analyzed by an automated video tracking system.

    Click to Show/Hide
Response regulation 6-hydroxydopamine (6-OHDA) treatment-induced ferroptosis in SH-SY5Y cells mainly by disturbing the protein expression of GPX4 and ACSL4. Collectively, the activation of the p62-Keap1-Nrf2 pathway prevents 6-OHDA-induced ferroptosis in SH-SY5Y cells, targeting this pathway in combination with a pharmacological inhibitor of ferroptosis can be a potential approach for parkinson's disease therapy.
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target [12]
Target for Ferroptosis Suppressor
Responsed Disease Parkinson's Disease [ICD-11: 8A00.0]
Responsed Regulator Sorting nexin-5 (SNX5) Driver
Pathway Response Glutathione metabolism hsa00480
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model PC12 cells Adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
In Vivo Model
All animal maintenance and experiments were approved by The Ethical Committee of Guangzhou University of Chinese Medicine. A total of 36 SD rats (Sprague-Dawley; male; 230-260 g; 8-9-weeks old) were divided randomly into two study groups (n = 18 rats/group), i.e., the sham group (unilateral injection of the equal volume of saline) and model group (unilateral injection of 20 g of 6-OHDA). All surgical procedures were performed under (10 mg/kgxylazine, and 100 mg/kg ketamine, intraperitoneal administration) anesthesia using stereotactic apparatus (RWD, Shenzhen, China). The rats received either unilateral injections of 5 ul of 6-OHDA (Sigma-Aldrich, Germany; 4 ug/ul, dissolved in PBS) or 5 ul of saline into MFB (left medial forebrain bundle) at the rate of 1 ul/min. Injection coordinates were as follows (with reference to bregma): anteroposterior (A/P) = - 2.2 mm, lateral (LAT) = 1.5 mm, and dorsoventral (D/V) = 8.0 mm. The rats were placed in animal holding room (humidity: 50 ± 5%; temperature: 21 ± 1 ; 12-h dark/light cycle).

    Click to Show/Hide
Response regulation This study investigated the mechanism by which PD-specific SE driven SNX5 promoted the ferroptosis level in Parkinson's disease models. The results showed that the GPX4 expression level significantly reduced.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
In total 3 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [2]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Thioctic acid Investigative
Responsed Regulator Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
PI3K-Akt signaling pathway hsa04151
Cell Process Cell ferroptosis
In Vitro Model PC12 cells Adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
Response regulation a-Lipoic acid (a-LA) suppressed cell viability decline and mitigated ferroptosis in an MPP-induced PC12 cell model of parkinson's disease (PD) via activating the PI3K/Akt/Nrf2 pathway. These results discovered a novel a-LA-based therapy for PD patients, and activating the PI3K/Akt/Nrf2 pathway might be developed as a promising therapeutic approach for PD.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [3]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug L. lactis MG1363-pMG36e-GLP-1 Investigative
Responsed Regulator Kelch-like ECH-associated protein 1 (KEAP1) Driver
Pathway Response Pathways in cancer hsa05200
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model Colon tissues (Mouse colon tissues)
hBCs (Brain cells)
In Vivo Model
Fifty male C57BL/6 mice provided by Hunan SJA Laboratory Animal Co., Ltd. (Changsha, China) resided in an animal house (temperature 26 ± 1 , humidity 50 ± 10%), in which the light was on for 12 h and off for 12 h. Mice were acclimatised for 1 week and allowed water and animal food with no limitations. Then, all mice were stochastically divided into 5 groups using random number tables available online (https://www.random-online.com/, accessed on 26 December 2021), including: (1) C group, a control group treated with normal saline for 7 consecutive days (n = 10); (2) M group, a model group with intraperitoneal injection of 20 mg/kg/day MPTP (Sigma-Aldrich, Taufkirchen, Germany, M0896) for 7 consecutive days (n = 10); (3) L group, treated with MPTP and 0.4 mg/kg/day liraglutide for 7 consecutive days (n = 10); (4) R group, treated with MPTP and 109 colony-forming unit (CFU) L. lactis MG1363 for 7 consecutive days via gavage (n = 10); (5) RG group, treated with MPTP and 109 CFUL. lactis MG1363-pMG36e-GLP-1 for 7 consecutive days via gavage (n = 10). All animals survived treatment and all animal experiments were administered from 9:00 to 12:00 in the morning to reduce systematic errors.

    Click to Show/Hide
Response regulation L. lactis MG1363-pMG36e-GLP-1 exerts neurotrophic effects via activating the Keap1/Nrf2/GPX4 signalling pathway to down-regulate ACSL4 and up-regulate FSP1 to suppress ferroptosis. These results indicated that the neurotrophic effects of the next-generation probiotics L. lactis MG1363-pMG36e-GLP-1 against MPTP-induced Parkinsonism are mediated by modulating oxidative stress, inhibiting ferroptosis, and redressing dysbiosis.
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target [13]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Gastrodin Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model C6 cells Malignant glioma Rattus norvegicus CVCL_0194
Response regulation Gastrodin induced GPX4, Nrf2 and HO-1 expression to protect C6 cells from H2O2-induced ferroptosis. Gastrodin pretreatment effectively reduced H2O2-induced oxidative damage, indicating gastrodin is a potential antioxidant that reduced cytotoxic ROS. The role of gastrodin in ferroptosis presents a new perspective for understanding parkinson's disease.
Cystine/glutamate transporter (SLC7A11)
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [4]
Target for Ferroptosis Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Cyperquat Investigative
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model PC12 cells Adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
Response regulation As a classic drug employed inin vitromodels of Parkinson's disease, 1-methyl-4-phenylpyridinium (MPP) can induce senescence in PC12 cells. The expression of the ferroptosis-related proteins ASCL4 was upregulated and FTH1 was downregulated, which promoted accumulation of lipid peroxides and eventually led to ferroptosis. By rescuing MPP-induced ferroptosis, cell senescence could be inhibited, and its molecular mechanism was related to a p53/SLC7A11/GPX4 signaling pathway.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [9]
Target for Ferroptosis Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Paraquat Investigative
Pathway Response Apoptosis hsa04210
Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell autophagy
Cell apoptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
Twenty male C57BL/6 mice at 12 weeks old were purchased from Hebei Medical University Experimental Animal Center. 10 mice of the experimental group were intraperitoneally injected with PQ (10 mg PQ (salt)/kg/dose) three times a week for 3 weeks according to the previous report. Ten mice of the control group were intraperitoneally injected with the same dose of normal saline. Once the experimental schedule was completed, firstly, the animals were used for behavioral tests. Then, the mice were anesthetized with 0.4% pentobarbital sodium (1 mL/100 g) solution and perfused. The substantia nigra tissue was exfoliated for subsequent experiments.

    Click to Show/Hide
Response regulation Paraquat (PQ) significantly caused the iron accumulation in cytoplasm and mitochondria through ferritinophagy pathway induced by NCOA4. Iron overload initiated lipid peroxidation through 12Lox, further inducing ferroptosis by producing lipid ROS. PQ downregulated SLC7A11 and GPX4 expression and upregulated Cox2 expression. Bcl2/Bax and P-p38/p38 pathways mediated the cross-talk between ferroptosis and apoptosis induced by PQ. These data further demonstrated the complexity of Parkinson's disease occurrence.
Unspecific Target
In total 5 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [5]
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Clioquinol Investigative
Responsed Regulator RAC-alpha serine/threonine-protein kinase (AKT1) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
PI3K-Akt signaling pathway hsa04151
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model SK-N-SH cells Neuroblastoma Homo sapiens CVCL_0531
In Vivo Model
In total, twelve healthy adult rhesus monkeys (Macaca mulatta lasiotis, aged 4-5 years, and weighed 3.5-5 kg at the start of the study) were obtained from Sichuan Primed Biological Technology Co., Ltd. Monkeys were randomly divided into two groups: normal (control) group (n = 3) and MPTP group (n = 9). Monkeys from MPTP group were administered with MPTP by intramuscular injection daily at the beginning of the study, and then the MPTP dose was gradually added to 0.5 mg/kg at the end of the experiment. Monkeys from control group were injected with saline instead, and the other conditions were the same with MPTP group.

    Click to Show/Hide
Response regulation Ferroptosis was probably involved in the pathogenesis of parkinson's disease (PD). Clioquinol (CQ) can decrease the excessive iron in the SN to normal level and directly protect DA neurons against oxidative stress probably by activating the AKT/mTOR survival pathway and blocking p53-medicated cell death.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [5]
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Clioquinol Investigative
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
PI3K-Akt signaling pathway hsa04151
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model SK-N-SH cells Neuroblastoma Homo sapiens CVCL_0531
In Vivo Model
In total, twelve healthy adult rhesus monkeys (Macaca mulatta lasiotis, aged 4-5 years, and weighed 3.5-5 kg at the start of the study) were obtained from Sichuan Primed Biological Technology Co., Ltd. Monkeys were randomly divided into two groups: normal (control) group (n = 3) and MPTP group (n = 9). Monkeys from MPTP group were administered with MPTP by intramuscular injection daily at the beginning of the study, and then the MPTP dose was gradually added to 0.5 mg/kg at the end of the experiment. Monkeys from control group were injected with saline instead, and the other conditions were the same with MPTP group.

    Click to Show/Hide
Response regulation Ferroptosis was probably involved in the pathogenesis of parkinson's disease (PD). Clioquinol (CQ) can decrease the excessive iron in the SN to normal level and directly protect DA neurons against oxidative stress probably by activating the AKT/mTOR survival pathway and blocking p53-medicated cell death.
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target [6]
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Ferric ammonium citrate Investigative
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
Pathway Response Fatty acid metabolism hsa01212
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model MES23.5 cells Normal Mus musculus CVCL_J351
In Vivo Model
Human a-synuclein (a-Syn) A53T overexpressiontransgenic mice(B6; C3-Tg (Prnp-SNCA*A53T) 83Vle/J) were originally obtained in breeding pairs from the Jackson Laboratory (004479) to generate a stable breeding colony. Animals were raised according to SPF level, kept at constant temperature (20 ± 2) , constant humidity (50 ± 10%), day and night cycle light (12-12 h), with free access to food and water.

    Click to Show/Hide
Response regulation Ferroptosis firstly occurred in a relatively low concentration of ferric ammonium citrate (FAC)-treated group, and then apoptosis appeared in response to the increased iron doses. This was also confirmed in vivo in parkinson's disease transgenic mice and the underlying mechanism might be associated with the p53 signaling pathway, but not MAPK signaling pathway.
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target [10]
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Regulator Adenosylhomocysteinase (AHCY) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
NCI-H292 cells Lung mucoepidermoid carcinoma Homo sapiens CVCL_0455
NCI-H838 cells Lung adenocarcinoma Homo sapiens CVCL_1594
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
KHOS cells Osteosarcoma Homo sapiens CVCL_2546
A2780 cells Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_0134
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by a subcutaneous injection of shRNA (control or DJ-1 KD) transfected H1299 cells (1,000,000/200 uL) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). Twelve days after injection, mice were randomly allocated into different groups and treated with vehicle (0.625% DMSO/99.375% HBSS (pH = 2)) or 30 mg/kg PE (tail intravenous injection, once every other day) for 16 days before the final tumor size was measured in all groups.

    Click to Show/Hide
Response regulation ACHYL1 is a interaction protein of DJ-1, which also has been known for negatively regulating SAHH (AHCY) activity via forming a heteromultimer complex. DJ-1 mutant neuronal cells experience high levels of ferroptosis, which might establish a potential mechanism via which DJ-1 could regulate early-onset recessive Parkinsons disease.
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target [15]
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Regulator Alpha-synuclein (SNCA) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model h-iPSCs (Human induced pluripotent stem cells)
hESCs (Human endometrial stromal cells)
Response regulation Variations in the SNCA gene that lead to increased -synuclein expression represent a genetic risk factor for sporadic parkinsons disease. a-synuclein aggregates may induce ferroptosis, and that inhibitors of ferroptosis prevent -synuclein-induced cell death.
Ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1)
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [7]
Target for Ferroptosis Driver
Responsed Disease Parkinson's Disease [ICD-11: 8A00.0]
Responsed Regulator NEAT1 (IncRNA) Driver
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SK-N-SH cells Neuroblastoma Homo sapiens CVCL_0531
Response regulation Dysregulated ferroptosis is closely associated with Parkinson's disease (PD) progression. NEAT1 functioned as a sponge to suppress miR-150-5p expression. Moreover, miR-150-5p overexpression suppressed ferroptosis in PD cell model. And miR-150-5p regulated SLC7A11 expression by directly binding to BAP1.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [7]
Target for Ferroptosis Driver
Responsed Disease Parkinson's Disease [ICD-11: 8A00.0]
Responsed Regulator hsa-miR-150-5p (miRNA) Suppressor
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SK-N-SH cells Neuroblastoma Homo sapiens CVCL_0531
Response regulation Dysregulated ferroptosis is closely associated with Parkinson's disease (PD) progression. NEAT1 functioned as a sponge to suppress miR-150-5p expression. Moreover, miR-150-5p overexpression suppressed ferroptosis in PD cell model. And miR-150-5p regulated SLC7A11 expression by directly binding to BAP1.
Solute carrier family 40 member 1 (SLC40A1)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [8]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Epigallocatechin Gallate Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell apoptosis
Response regulation Epigallocatechin-3-Gallate (EGCG) pretreatment counteracted 6-OHDA-induced increased expression of divalent metal transporter-1 (DMT1) and hepcidin and decreased expression of the iron-export protein ferroportin 1 (Fpn1), leading to a 28% reduction in Fe2+ uptake. EGCG inhibits iron overload, decreased LPO, and increased GSH levels in Parkinson disease models, which are the three major hallmarks of ferroptosis.
Prostaglandin G/H synthase 2 (PTGS2)
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [9]
Target for Ferroptosis Marker
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Paraquat Investigative
Pathway Response Apoptosis hsa04210
Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell autophagy
Cell apoptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
Twenty male C57BL/6 mice at 12 weeks old were purchased from Hebei Medical University Experimental Animal Center. 10 mice of the experimental group were intraperitoneally injected with PQ (10 mg PQ (salt)/kg/dose) three times a week for 3 weeks according to the previous report. Ten mice of the control group were intraperitoneally injected with the same dose of normal saline. Once the experimental schedule was completed, firstly, the animals were used for behavioral tests. Then, the mice were anesthetized with 0.4% pentobarbital sodium (1 mL/100 g) solution and perfused. The substantia nigra tissue was exfoliated for subsequent experiments.

    Click to Show/Hide
Response regulation Paraquat (PQ) significantly caused the iron accumulation in cytoplasm and mitochondria through ferritinophagy pathway induced by NCOA4. Iron overload initiated lipid peroxidation through 12Lox, further inducing ferroptosis by producing lipid ROS. PQ downregulated SLC7A11 and GPX4 expression and upregulated Cox2 expression. Bcl2/Bax and P-p38/p38 pathways mediated the cross-talk between ferroptosis and apoptosis induced by PQ. These data further demonstrated the complexity of Parkinson's disease occurrence.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [10]
Target for Ferroptosis Marker
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Regulator Parkinson disease protein 7 (PARK7) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
NCI-H292 cells Lung mucoepidermoid carcinoma Homo sapiens CVCL_0455
NCI-H838 cells Lung adenocarcinoma Homo sapiens CVCL_1594
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
KHOS cells Osteosarcoma Homo sapiens CVCL_2546
A2780 cells Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_0134
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by a subcutaneous injection of shRNA (control or DJ-1 KD) transfected H1299 cells (1,000,000/200 uL) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). Twelve days after injection, mice were randomly allocated into different groups and treated with vehicle (0.625% DMSO/99.375% HBSS (pH = 2)) or 30 mg/kg PE (tail intravenous injection, once every other day) for 16 days before the final tumor size was measured in all groups.

    Click to Show/Hide
Response regulation KD of DJ-1 (PARK7) increases ferroptosis as PTGS2 levels increased. DJ-1 mutant neuronal cells experience high levels of ferroptosis, which might establish a potential mechanism via which DJ-1 could regulate early-onset recessive Parkinsons disease.
Polyunsaturated fatty acid lipoxygenase ALOX12 (ALOX12)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [9]
Target for Ferroptosis Driver
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Paraquat Investigative
Pathway Response Apoptosis hsa04210
Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell autophagy
Cell apoptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
Twenty male C57BL/6 mice at 12 weeks old were purchased from Hebei Medical University Experimental Animal Center. 10 mice of the experimental group were intraperitoneally injected with PQ (10 mg PQ (salt)/kg/dose) three times a week for 3 weeks according to the previous report. Ten mice of the control group were intraperitoneally injected with the same dose of normal saline. Once the experimental schedule was completed, firstly, the animals were used for behavioral tests. Then, the mice were anesthetized with 0.4% pentobarbital sodium (1 mL/100 g) solution and perfused. The substantia nigra tissue was exfoliated for subsequent experiments.

    Click to Show/Hide
Response regulation Paraquat (PQ) significantly caused the iron accumulation in cytoplasm and mitochondria through ferritinophagy pathway induced by NCOA4. Iron overload initiated lipid peroxidation through 12Lox, further inducing ferroptosis by producing lipid ROS. PQ downregulated SLC7A11 and GPX4 expression and upregulated Cox2 expression. Bcl2/Bax and P-p38/p38 pathways mediated the cross-talk between ferroptosis and apoptosis induced by PQ. These data further demonstrated the complexity of Parkinson's disease occurrence.
Nuclear receptor coactivator 4 (NCOA4)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [9]
Target for Ferroptosis Driver
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Paraquat Investigative
Pathway Response Apoptosis hsa04210
Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell autophagy
Cell apoptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
Twenty male C57BL/6 mice at 12 weeks old were purchased from Hebei Medical University Experimental Animal Center. 10 mice of the experimental group were intraperitoneally injected with PQ (10 mg PQ (salt)/kg/dose) three times a week for 3 weeks according to the previous report. Ten mice of the control group were intraperitoneally injected with the same dose of normal saline. Once the experimental schedule was completed, firstly, the animals were used for behavioral tests. Then, the mice were anesthetized with 0.4% pentobarbital sodium (1 mL/100 g) solution and perfused. The substantia nigra tissue was exfoliated for subsequent experiments.

    Click to Show/Hide
Response regulation Paraquat (PQ) significantly caused the iron accumulation in cytoplasm and mitochondria through ferritinophagy pathway induced by NCOA4. Iron overload initiated lipid peroxidation through 12Lox, further inducing ferroptosis by producing lipid ROS. PQ downregulated SLC7A11 and GPX4 expression and upregulated Cox2 expression. Bcl2/Bax and P-p38/p38 pathways mediated the cross-talk between ferroptosis and apoptosis induced by PQ. These data further demonstrated the complexity of Parkinson's disease occurrence.
Natural resistance-associated macrophage protein 2 (SLC11A2)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [8]
Target for Ferroptosis Driver
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Epigallocatechin Gallate Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell apoptosis
Response regulation Epigallocatechin-3-Gallate (EGCG) pretreatment counteracted 6-OHDA-induced increased expression of divalent metal transporter-1 (DMT1) and hepcidin and decreased expression of the iron-export protein ferroportin 1 (Fpn1), leading to a 28% reduction in Fe2+ uptake. EGCG inhibits iron overload, decreased LPO, and increased GSH levels in Parkinson disease models, which are the three major hallmarks of ferroptosis.
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [3]
Target for Ferroptosis Driver
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug L. lactis MG1363-pMG36e-GLP-1 Investigative
Pathway Response Pathways in cancer hsa05200
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model Colon tissues (Mouse colon tissues)
hBCs (Brain cells)
In Vivo Model
Fifty male C57BL/6 mice provided by Hunan SJA Laboratory Animal Co., Ltd. (Changsha, China) resided in an animal house (temperature 26 ± 1 , humidity 50 ± 10%), in which the light was on for 12 h and off for 12 h. Mice were acclimatised for 1 week and allowed water and animal food with no limitations. Then, all mice were stochastically divided into 5 groups using random number tables available online (https://www.random-online.com/, accessed on 26 December 2021), including: (1) C group, a control group treated with normal saline for 7 consecutive days (n = 10); (2) M group, a model group with intraperitoneal injection of 20 mg/kg/day MPTP (Sigma-Aldrich, Taufkirchen, Germany, M0896) for 7 consecutive days (n = 10); (3) L group, treated with MPTP and 0.4 mg/kg/day liraglutide for 7 consecutive days (n = 10); (4) R group, treated with MPTP and 109 colony-forming unit (CFU) L. lactis MG1363 for 7 consecutive days via gavage (n = 10); (5) RG group, treated with MPTP and 109 CFUL. lactis MG1363-pMG36e-GLP-1 for 7 consecutive days via gavage (n = 10). All animals survived treatment and all animal experiments were administered from 9:00 to 12:00 in the morning to reduce systematic errors.

    Click to Show/Hide
Response regulation L. lactis MG1363-pMG36e-GLP-1 exerts neurotrophic effects via activating the Keap1/Nrf2/GPX4 signalling pathway to down-regulate ACSL4 and up-regulate FSP1 to suppress ferroptosis. These results indicated that the neurotrophic effects of the next-generation probiotics L. lactis MG1363-pMG36e-GLP-1 against MPTP-induced Parkinsonism are mediated by modulating oxidative stress, inhibiting ferroptosis, and redressing dysbiosis.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [11]
Target for Ferroptosis Driver
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Oxidopamine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
The AB strain of wild-type zebrafish (Danio rerio) was applied in this study. Zebrafish larvae at 4 dpf (days post-fertilization) were co-incubated with 250 uM 6-OHDA or 1.5 ug/mL nomifensine (Nomi, a dopamine transporter inhibitor) in 6-well plates at a density of 30 zebrafish embryos per group for 2 days and the medium was refreshed every day. The swimming total distance of each fish was recorded for 10 min and was analyzed by an automated video tracking system.

    Click to Show/Hide
Response regulation 6-hydroxydopamine (6-OHDA) treatment-induced ferroptosis in SH-SY5Y cells mainly by disturbing the protein expression of GPX4 and ACSL4. Collectively, the activation of the p62-Keap1-Nrf2 pathway prevents 6-OHDA-induced ferroptosis in SH-SY5Y cells, targeting this pathway in combination with a pharmacological inhibitor of ferroptosis can be a potential approach for parkinson's disease therapy.
Heme oxygenase 1 (HMOX1)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [13]
Target for Ferroptosis Driver/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug Gastrodin Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model C6 cells Malignant glioma Rattus norvegicus CVCL_0194
Response regulation Gastrodin induced GPX4, Nrf2 and HO-1 expression to protect C6 cells from H2O2-induced ferroptosis. Gastrodin pretreatment effectively reduced H2O2-induced oxidative damage, indicating gastrodin is a potential antioxidant that reduced cytotoxic ROS. The role of gastrodin in ferroptosis presents a new perspective for understanding parkinson's disease.
Ferroptosis suppressor protein 1 (AIFM2)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [3]
Target for Ferroptosis Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Drug L. lactis MG1363-pMG36e-GLP-1 Investigative
Pathway Response Pathways in cancer hsa05200
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model Colon tissues (Mouse colon tissues)
hBCs (Brain cells)
In Vivo Model
Fifty male C57BL/6 mice provided by Hunan SJA Laboratory Animal Co., Ltd. (Changsha, China) resided in an animal house (temperature 26 ± 1 , humidity 50 ± 10%), in which the light was on for 12 h and off for 12 h. Mice were acclimatised for 1 week and allowed water and animal food with no limitations. Then, all mice were stochastically divided into 5 groups using random number tables available online (https://www.random-online.com/, accessed on 26 December 2021), including: (1) C group, a control group treated with normal saline for 7 consecutive days (n = 10); (2) M group, a model group with intraperitoneal injection of 20 mg/kg/day MPTP (Sigma-Aldrich, Taufkirchen, Germany, M0896) for 7 consecutive days (n = 10); (3) L group, treated with MPTP and 0.4 mg/kg/day liraglutide for 7 consecutive days (n = 10); (4) R group, treated with MPTP and 109 colony-forming unit (CFU) L. lactis MG1363 for 7 consecutive days via gavage (n = 10); (5) RG group, treated with MPTP and 109 CFUL. lactis MG1363-pMG36e-GLP-1 for 7 consecutive days via gavage (n = 10). All animals survived treatment and all animal experiments were administered from 9:00 to 12:00 in the morning to reduce systematic errors.

    Click to Show/Hide
Response regulation L. lactis MG1363-pMG36e-GLP-1 exerts neurotrophic effects via activating the Keap1/Nrf2/GPX4 signalling pathway to down-regulate ACSL4 and up-regulate FSP1 to suppress ferroptosis. These results indicated that the neurotrophic effects of the next-generation probiotics L. lactis MG1363-pMG36e-GLP-1 against MPTP-induced Parkinsonism are mediated by modulating oxidative stress, inhibiting ferroptosis, and redressing dysbiosis.
Ferritin heavy chain (FTH1)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [14]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease [ICD-11: 8A00]
Responsed Regulator rno-miR-335 (miRNA) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model PC12 cells Adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
In Vivo Model
A total of 48 male Sprague-Dawley rats (weighing, 180-220 g; 6-8 weeks of age) were purchased from the Animal Center of Guangzhou University of Chinese Medicine (Guangzhou, China). The rats were anesthetized (100 mg/kg ketamine and 10 mg/kg xylazine, intraperitoneal injection) and placed in a stereotaxic apparatus with the skull flat. An intracerebral injection of 6-OHDA was performed at 2 sites in the right SN pars compacta (SNpc) and ventral tegmental area (VTA): Anteroposterior (A/P)=-4.9 mm; mediolateral (M/L)=-1.9 mm; dorsoventral (D/V)=-7.5 mm; and anteroposterior (A/P)=-4.9 mm; mediolateral (M/L)=-1.1 mm; dorsoventral (D/V)=8.0 mm. During the surgery, body temperature was maintained at ~36.5 using a heating pad. All rats received meticulous post-operative care.

    Click to Show/Hide
Response regulation MiR335 promotes ferroptosis by targeting FTH1 inin vitroandin vivomodels of Parkinson's disease, providing a potential therapeutic target for the treatment of PD. Mechanistically, miR335 enhanced ferroptosis through the degradation of FTH1 to increase iron release, lipid peroxidation and reactive oxygen species (ROS) accumulation, and to decrease mitochondrial membrane potential (MMP).
References
Ref 1 Thioredoxin-1 Rescues MPP(+)/MPTP-Induced Ferroptosis by Increasing Glutathione Peroxidase 4. Mol Neurobiol. 2021 Jul;58(7):3187-3197. doi: 10.1007/s12035-021-02320-1. Epub 2021 Feb 26.
Ref 2 -Lipoic acid alleviates ferroptosis in the MPP(+) -induced PC12 cells via activating the PI3K/Akt/Nrf2 pathway. Cell Biol Int. 2021 Feb;45(2):422-431. doi: 10.1002/cbin.11505. Epub 2020 Dec 8.
Ref 3 Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson's Disease via Inhibiting Ferroptosis. Nutrients. 2022 Nov 18;14(22):4886. doi: 10.3390/nu14224886.
Ref 4 p53-mediated ferroptosis is required for 1-methyl-4-phenylpyridinium-induced senescence of PC12 cells. Toxicol In Vitro. 2021 Jun;73:105146. doi: 10.1016/j.tiv.2021.105146. Epub 2021 Mar 15.
Ref 5 Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. Aging (Albany NY). 2020 May 18;12(10):9515-9533. doi: 10.18632/aging.103225. Epub 2020 May 18.
Ref 6 Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson's disease. Free Radic Biol Med. 2020 May 20;152:227-234. doi: 10.1016/j.freeradbiomed.2020.03.015. Epub 2020 Mar 23.
Ref 7 LncRNA NEAT1 promoted MPP+induced ferroptosis via regulating miR1505p/BAP1 pathway in SKNSH cells. Acta Neurobiol Exp (Wars). 2022;82(2):226-236. doi: 10.55782/ane-2022-021.
Ref 8 Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease. Front Pharmacol. 2022 Sep 12;13:977521. doi: 10.3389/fphar.2022.977521. eCollection 2022.
Ref 9 Ferritinophagy-Mediated Ferroptosis Involved in Paraquat-Induced Neurotoxicity of Dopaminergic Neurons: Implication for Neurotoxicity in PD. Oxid Med Cell Longev. 2021 Jul 26;2021:9961628. doi: 10.1155/2021/9961628. eCollection 2021.
Ref 10 DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nat Commun. 2020 Mar 6;11(1):1251. doi: 10.1038/s41467-020-15109-y.
Ref 11 Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells. Mol Neurobiol. 2020 Nov;57(11):4628-4641. doi: 10.1007/s12035-020-02049-3. Epub 2020 Aug 8.
Ref 12 Super-enhancer-driven Sorting Nexin 5 expression promotes dopaminergic neuronal ferroptosis in Parkinson's disease models. Biochem Biophys Res Commun. 2021 Aug 27;567:35-41. doi: 10.1016/j.bbrc.2021.06.024. Epub 2021 Jun 13.
Ref 13 Gastrodin Inhibits H(2)O(2)-Induced Ferroptosis through Its Antioxidative Effect in Rat Glioma Cell Line C6. Biol Pharm Bull. 2020;43(3):480-487. doi: 10.1248/bpb.b19-00824.
Ref 14 miR335 promotes ferroptosis by targeting ferritin heavy chain 1 in invivo and invitro models of Parkinson's disease. Int J Mol Med. 2021 Apr;47(4):61. doi: 10.3892/ijmm.2021.4894. Epub 2021 Mar 2.
Ref 15 Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell Death Differ. 2020 Oct;27(10):2781-2796. doi: 10.1038/s41418-020-0542-z. Epub 2020 Apr 27.